EUVIMEDEUVIMED entdecken
Crossref

Nab-paclitaxel is a valuable NSCLC therapy option

Charu Aggarwal

The Journal of Community and Supportive Oncology · 2013

DOI: 10.12788/j.cmonc.0042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Community and Supportive Oncology, 2013. Verfasst von Charu Aggarwal.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Aggarwal, C. (2013). Nab-paclitaxel is a valuable NSCLC therapy option. The Journal of Community and Supportive Oncology. https://doi.org/10.12788/j.cmonc.0042

Vancouver

Aggarwal C. Nab-paclitaxel is a valuable NSCLC therapy option. The Journal of Community and Supportive Oncology. 2013. doi:10.12788/j.cmonc.0042

BibTeX
@article{Aggarwal2013,
  author = {Aggarwal, Charu},
  title = {Nab-paclitaxel is a valuable NSCLC therapy option},
  journal = {The Journal of Community and Supportive Oncology},
  year = {2013},
  doi = {10.12788/j.cmonc.0042}
}
Kostenlos starten →